21861 U.S

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: FRAV2003/0007 US

INVENTORS: Antony Bigot, et al

TITLE: 4-Substituted Quinoline Derivatives,
Method And Intermediates For Their Preparation
And Pharmaceutical Compositions Containing Them

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

Date of Deposit

EL964823123US

Express Mail N

16834 U.S. PTO 10/810711

ADDI	ICV.	TION	FII	FMFNTS

1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)						
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	96				
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets					
4.	Oath a.	or Declaration Unexecuted (original or copy)	Total Pages	2				
	b.	Copy from a prior application (37 CFR § 1.63(d))						
		i. DELETION OF INVENTOR(S) Signed statement attached deleting application, see 37 CFR §§ 1.63(d)(2)		ned in the pric				
5.	Powe	er of Attorney	Total Pages					
	a.	Newly executed (original or copy)						
	b.	Copy from a prior application (37 CFR § 1	.63(d))					
6.		Microfiche Computer Program (Appendix)						

Page							
7.	Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to computer copy) c. Statement verifying identity of above copies						
	If a CONTINUING Application, check appropriate box, and supply the requisite information: Continuation Divisional Continuation-in-part of prior application no:, filed, Examiner, Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).						
\boxtimes	This application claims the benefit of U.S. Provisional Application No. 60/487,084, filed July 14, 2003, and claims priority of French Application No. 0303812 filed March 28, 2003. (The cross reference has been/will be inserted on page one of the specification).						
	Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.						
ACC	OMPANYING APPLICATION PARTS						
7. 8. 9.	Assignment Papers (cover sheet & document(s)) 37 CFR §3.73(b) Statement (when there is an assignee) Verified English Translation Document (if applicable)						
10.	Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449						
11. 12.	Preliminary Amendment Return Receipt Postcard (MPEP 503) (Should be specifically itemized)						
13.	*Small Entity Statement(s) (PTO/SB/09-12) Statement filed in prior application, Status still proper and desired						
14.	Certified Copy of Priority Document(s) 0303812 (if foreign priority is claimed)						
15.	Other: Application Data Sheet						
COR	RESPONDENCE ADDRESS						
\boxtimes	Customer Number or Bar Code Label 005487						
	(Insert Customer No. or Attach bar code label here)						
	Joseph Strupczewski, Reg. No. 50,903						

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2387
Telefax (908) 231-2626
Aventis Docket No. FRAV2003-0007 US NP

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANS		Complete if Known			
LEE I LAIN	DIVILLI AL	Application Number	Not Yet Assigned		
	2004	Filing Date	Concurrently Filed Herewith Antony Bigot, et al		
for FY 2	2004	First Named Inventor			
Patent fees are subject to	annual revision.	Examiner Name			
Applicant claims small entity status	s. See 37 CFR 1.27	Group / Art Unit			
TOTAL AMOUNT OF PAYMENT (\$) 770.00		Attorney Docket No.	FRAV2003-0007 US NP		

METHOD OF PAYMENT (check all that apply)				FEE CALCULATION (continued)						
Check Credit Card Money Other None				3. ADDITIONAL FEES						
Order Deposit Account			Large Er	ntity	Small E	ntity				
Deposit Account	eposit		Fee Code	Fee (\$)	Fee Code	Fee (\$)				
Number Deposit	imber 10-1702					(*)		(4)	Fee Description	Fee Paid
Account Name	Av	entis Phari	naceuticals I	nc.	1051	130	2051	65	Surcharge - late filing fee or oath	
The Commiss									Surcharge - late provisional filing fee or	
	s) indicated t		Credit any ove		1052 1053	50 130	2052 1053	25 130	cover sheet Non-English Specification	<u> </u>
	additional fe	e(s) during the	pendency of the	nis application	1812	2,520	1812	2,520	For filing a request for reexamination	
			for the filing fo	99	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
to the above-identified deposit account FEE CALCULATION				1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action		
1. BASIC FI				_	1251	110	2251	55	Extension for reply within first month	
Large Entity Fee Fee Code (\$)			escription	Fee Paid	1252	420	2252	205	Extension for reply within second month	
1001 770			filing fee	770	1253	950	2253	465	Extension for reply within third month	
1002 340	2002	165 Desig	n filing Fee		1254	1,480	2254	725	Extension for reply within fourth month	
1003 530	2003	260 Plant	filing fee		1255	2,010	2255	985	Extension for reply within fifth month	
1004 770			ue filing fee		1401	330	2401	160	Notice of Appeal	
1005 160	2005	80 Provis	sional filing fee		1402	330	2402	160	Filing a brief in support of an appeal	
	SUBT	OTAL (1)	(\$) 770.	00	1403	290	2403	140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			1451	1,510	1451	1,510	Petition to institute a public use proceeding			
		Extra	Fee from	Fee	1452	110	2452	55	Petition to revive - unavoidable	
Total Claims 1	5 -20*	Claims *= 0	below x 18	Paid	1453	1,330	2453	650	Petition to revive - unintentional	
Independent 3	- 3*	·*= 0	x 86	= 0	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims					1502	480	2502	235	Design issue fee	
Multiple Depende	ent		0	= 0	1503	640	2503	315	Plant issue fee	
	0	4.a			1460	130 50	1460	130	Petitions to the Commissioner	
Large Entity Fee Fee	Small En	Fee			1807	50	1807	50	Petitions related to provisional applications	
Code (\$) 1202 18	Code 2202	(+)	escription s in excess of 2	О	1806	180	1806	180	Submission of Information Disclosure	
1201 86	2201	42 Indep	endent claims i	n excess of 3	8021	40	8021	40	Recording each patent assignment per	
1203 290	2203	140 Multip	Multiple dependent claim, if not		1809	770	2809	375	property (times number of properties) Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86	2204	42 **Reis	sue independe		1810	770	2810	375	For each additional invention to be	
1205 18	claims over original patent 2205 9 **Reissue claims in excess of 20 and over original patent			1801	770	2801	375	examined (37 CFR § 1.129(b)) Request for Continued Examination (RCE)		
			ū		1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 0.00				Other fee	(specify)					
**or number previously paid, if greater; For Reissues, see above			*Reduce	d by Basic	Filing Fee	Paid	SUBTOTAL (3) (\$)			

SUBMITTED BY

Name (Print/Type) | Joseph Strupczewski, Reg. No. 50,903 | Registration No. (Attomey/Agent) | Date | 03/16/2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.